A recently-discovered NMDA receptor gene, GRIN3B, is associated with duration mismatch negativity

Psychiatry Research

Volumn 218, Issue 3, 2014, Pages 356-358

  Lin, Yi Ting ^a,b   Hsieh, Ming H ^a,b   Liu, Chen Chung ^a,b   Hwang, Tzung Jeng ^a,b   Chien, Yi Ling ^b   Hwu, Hai Gwo ^a,b   Liu, Chih Min ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

EEG; ERP; Glutamate; Mismatch negativity; MMN; NMDA; Schizophrenia; SNP

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NERVE PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; ELECTROENCEPHALOGRAPHY; FEMALE; GENE; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOTYPE; GRIN1 GENE; GRIN2B GENE; GRIN3B GENE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH NEGATIVITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; REFERENCE VALUE;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, N-METHYL-D-ASPARTATE; REFERENCE VALUES; SCHIZOPHRENIA;

EID: 84902082153     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.04.032     Document Type: Article

References (12)

1. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B.C. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 2010, 67:255-262.
2. Light G.A., Williams L.E., Minow F., Sprock J., Rissling A., Sharp R., Swerdlow N.R., Braff D.L. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Current Protocols in Neuroscience 2010, 21-24. (Chapter 6, Unit 6.25).
3. Lin Y.-T., Liu C.-M., Chiu M.-J., Liu C.-C., Chien Y.-L., Hwang T.-J., Jaw F.-S., Shan J.-C., Hsieh M.H., Hwu H.-G. Differentiation of schizophrenia patients from healthy subjects by mismatch negativity and neuropsychological tests. PLoS One 2012, 7:e34454.
4. Luck S.J. Is it legitimate to compare conditions with different numbers of trials? (accessed 17.03.14). http://erpinfo.org/Members/sjluck/Mean_Peak_Noise.pdf.
5. Matsuda K., Kamiya Y., Matsuda S., Yuzaki M. Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Brain Research. Molecular Brain Research 2002, 100:43-52.
6. Naatanen R., Winkler I. The concept of auditory stimulus representation in cognitive neuroscience. Psychological Bulletin 1999, 125:826-859.
7. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., De Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. American Journal Human Genetics 2007, 81:559-575.
8. Salisbury D.F., Kuroki N., Kasai K., Shenton M.E., Mccarley R.W. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Archives of General Psychiatry 2007, 64:521-529.
9. Smothers C.T., Woodward J.J. Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. Journal of Pharmacology & Experimental Therapeutics 2007, 322:739-748.
10. Sodhi M., Wood K.H., Meador-Woodruff J. Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Review of Neurotherapeutics 2008, 8:1389-1406.
11. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophrenia Bulletin 2007, 33:69-94.
12. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Archives of General Psychiatry 2000, 57:1139-1147.